STAT Plus: Regeneron is buying back $1 billion in stock, but hell has not yet frozen over
A version of this story appeared in STAT’s biotech newsletter, The Readout. Sign up here.
Regeneron Pharmaceuticals yesterday announced it would spend $1 billion buying its own stock, a move that was both unremarkable and remarkable at the same time.